NTRB - Nutriband Inc. Stock Price, Fair Value and News

$4.46-0.16 (-3.46%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NTRB Price Action

Last 7 days

-8.0%

Last 30 days

-28.3%

Last 90 days

-28.4%

Trailing 12 Months

7.7%

NTRB RSI Chart

NTRB Valuation

Market Cap

53.7M

Price/Earnings (Trailing)

-5.23

Price/Sales (Trailing)

20.82

EV/EBITDA

-4.67

Price/Free Cashflow

-10.84

NTRB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NTRB Fundamentals

NTRB Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

40.56%

Rev. Growth (Qtr)

-6.74%

NTRB Earnings

Earnings (TTM)

-10.3M

Earnings Growth (Yr)

-17.29%

Earnings Growth (Qtr)

-44.03%

NTRB Profitability

Operating Margin

34.36%

EBT Margin

-398.29%

Return on Equity

-120.89%

Return on Assets

-100.9%

Free Cashflow Yield

-9.22%

NTRB Investor Care

Shares Dilution (1Y)

8.46%

Diluted EPS (TTM)

-2.87

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.1M	2.4M	2.6M	0
2024	2.1M	2.0M	1.8M	2.0M
2023	2.1M	2.1M	2.1M	2.1M
2022	1.4M	1.5M	1.7M	2.0M
2021	943.7K	1.3M	1.4M	1.3M
2020	370.6K	296.4K	306.0K	615.2K
2019	245.3K	276.6K	308.0K	339.3K
2018	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

CEO	Mr. Gareth Sheridan
WEBSITE	https://nutriband.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

Nutriband Inc. Frequently Asked Questions

What is the ticker symbol for Nutriband Inc.? What does NTRB stand for in stocks?

NTRB is the stock ticker symbol of Nutriband Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nutriband Inc. (NTRB)?

As of Wed Dec 03 2025, market cap of Nutriband Inc. is 53.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NTRB stock?

You can check NTRB's fair value in chart for subscribers.

Is Nutriband Inc. a good stock to buy?

The fair value guage provides a quick view whether NTRB is over valued or under valued. Whether Nutriband Inc. is cheap or expensive depends on the assumptions which impact Nutriband Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTRB.

What is Nutriband Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NTRB's PE ratio (Price to Earnings) is -5.23 and Price to Sales (PS) ratio is 20.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTRB PE ratio will change depending on the future growth rate expectations of investors.